Alicia Secor - 04 Jun 2026 Form 4 Insider Report for ZEVRA THERAPEUTICS, INC. (ZVRA)

Reporting relationship: Director
Issuer ticker: ZVRA
Reported as of: 04 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jun 2026, 16:16:18 UTC
Prior SEC filing: 09 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Alicia Secor

Key filing fact

Alicia Secor filed Form 4 for ZEVRA THERAPEUTICS, INC. (ZVRA) on 18 Jun 2026.

Key facts

This page summarizes Alicia Secor's Form 4 filing for ZEVRA THERAPEUTICS, INC. (ZVRA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Jun 2026, 16:16.

Change

Previous filing in this sequence was filed on 09 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001584516 Primary reporting owner

Secor Alicia

Relationship: Director
Address: C/O ZEVRA THERAPEUTICS, INC., 101 FEDERAL STREET, BOSTON
Signature: /s/ Timothy J. Sangiovanni, Attorney-in-Fact for Alicia Secor
Signature date: 18 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZVRA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +30,000
Change %
Price: $0.000000^*
Shares after: 30,000
Date: 04 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $11.17
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, June 4, 2026.

Footnote F2

This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy.

Footnote F3

One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date.